gefitinib has been researched along with Neoplasms, Squamous Cell in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Costa, DB; Gandhi, L; Gerber, DE | 1 |
| Gooding, WE; Grandis, JR; Gubish, CT; Siegfried, JM; Stabile, LP; Xu, H | 1 |
| Hasegawa, Y; Kumasaka, R; Nakamura, M; Nakamura, N; Okumura, K; Osawa, H; Shirato, K; Takanashi, S; Tamura, M; Yamabe, H | 1 |
| Guo, M; Liu, S; Lu, F | 1 |
| Chang, GC; Chen, KC; Gow, CH; Hsu, C; Lin, CP; Shih, JY; Su, WP; Yang, CH; Yang, PC; Yang, TY; Yu, CJ | 1 |
1 review(s) available for gefitinib and Neoplasms, Squamous Cell
| Article | Year |
|---|---|
Management and future directions in non-small cell lung cancer with known activating mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Mutation Rate; Neoplasms, Squamous Cell; Oncogenes; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2014 |
4 other study(ies) available for gefitinib and Neoplasms, Squamous Cell
| Article | Year |
|---|---|
Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Hepatocyte Growth Factor; Humans; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neoplasms, Squamous Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transforming Growth Factor alpha; Wound Healing; Xenograft Model Antitumor Assays | 2011 |
Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy.
Topics: Aged; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasms, Squamous Cell; Nephrotic Syndrome; Quinazolines | 2004 |
Gefitinib-sensitizing mutations in esophageal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; DNA, Neoplasm; ErbB Receptors; Esophageal Diseases; Esophageal Neoplasms; Gefitinib; Humans; Mutation; Neoplasms, Squamous Cell; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger | 2006 |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasms, Squamous Cell; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Smoking; Survival Analysis; Survival Rate; Treatment Outcome | 2006 |